Report overview
This report contains market size and forecasts of Resistant Pseudomonas Aeruginosa Infections Drugs in global, including the following market information:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Resistant Pseudomonas Aeruginosa Infections Drugs companies in 2021 (%)
The global Resistant Pseudomonas Aeruginosa Infections Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Semi-Synthetic Penicillin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs include ContraFect Corp, Inhibrx LP, Achaogen Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Novartis AG, AmpliPhi Biosciences Corp, Biolytics Pharma and Shionogi & Co Ltd. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Type, 2021 (%)
Semi-Synthetic Penicillin
Cephalosporin
Lactam Drugs
Others
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Home Care
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues share in global market, 2021 (%)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
ContraFect Corp
Inhibrx LP
Achaogen Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Novartis AG
AmpliPhi Biosciences Corp
Biolytics Pharma
Shionogi & Co Ltd
